Market Trading Terminal · RC10
Key risk: Delayed or incomplete Q2 earnings reporting
AI updated 6/29/2026, 12:15:33 AM
Microstructure, quotes, and decision memory
Live market activity from the aggregated feed. Two-sided quotes appear when an order book is available for this market.
Who contributed to this decision
| Provider | Score | Accuracy | On this market |
|---|---|---|---|
| fincept | 1 | — | Active |
| oryn_db | — | — | Active |
| polymarket | — | — | Active |
| mistral | — | — | Active |
| news | 1 | — | Global only |
| social | 1 | — | Global only |
| economic_calendar | 1 | — | Global only |
| trends | 1 | — | Global only |
| google_trends | 1 | — | Global only |
ORYN polls Claude, GPT, Gemini and more — consensus appears as models respond.
Crowd Consensus
52%
ORYN Consensus
52%
Signal Score
0.0
Opportunity
0.0
Related markets and connected predictions
Simulated execution for this market
Quality score
50/100
Fill rate
100%
Executions
112
Avg slippage
5414 bps
Open positions
0
Latency
520ms
Platform-wide model improvement
Events
1,331,250
Trades learned
112
Strategies
4
Providers scored
8
Counterfactual strategy simulations
No replay comparisons for this market yet. Replay runs as markets resolve and accumulate snapshots. Replay lab →
MEDIUM
EV 0.0¢
Entry: 48-55
—
Resolution
16d
Decision snapshots
0
Price history
2 points
This market will resolve to "Yes" if Johnson & Johnson's MedTech revenue for the upcoming second fiscal quarter, as reported in its official company earnings materials, is above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is Johnson & Johnson's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Crowd-implied vs ORYN AI fair value over time, with decision markers
The prediction market suggests a near-even split on whether Johnson & Johnson's Q2 MedTech revenue will exceed $9B, with a slight bullish lean at 51.50%. Resolution hinges on precise Q2 earnings reporting by August 31, 2026, with strict adherence to official materials.
JNJ's MedTech segment may outperform due to strong demand in surgical robotics, interventional solutions, and diabetes care, driven by post-pandemic recovery and innovation in minimally invasive technologies. Analysts anticipate sustained growth in high-margin segments like orthopedics and vision care, potentially pushing revenue above $9B.
Macroeconomic pressures, supply chain disruptions, or weaker-than-expected demand in key MedTech markets could suppress revenue below $9B. Regulatory hurdles or competitive pressures in core segments like surgical tools may also dampen growth prospects.
Regime: — · Confidence: 0%
Trade links and live readiness
Route to regulated venues when you are ready. ORYN never holds your funds.
ORYN does not hold funds or execute trades. You will be redirected to a third-party regulated venue.
No comments yet.
